View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
November 7, 2011

Aslan and Bristol-Myers Squibb partner for cancer drug development

Aslan Pharmaceuticals has entered into an agreement with Bristol-Myers Squibb to develop an investigational small molecule inhibitor of MET receptor tyrosine kinase, BMS-777607, for treating solid tumours.

Aslan Pharmaceuticals has entered into an agreement with Bristol-Myers Squibb to develop an investigational small molecule inhibitor of MET receptor tyrosine kinase, BMS-777607, for treating solid tumours.

Aslan will have rights to develop and market BMS-777607 in Australia, China, Korea, Taiwan and other Asian countries, while Bristol-Myers Squibb will retain rights in the rest of the countries.

Under a pre-agreed development programme, the two parties will develop BMS-777607 against gastric cancer and lung cancer.

Francis Cuss, senior vice-president of research at Bristol-Myers Squibb, said that the partnership will work to produce high-quality data that may be used to further develop and commercialise the medicine worldwide.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena